AbbVie to buy Cerevel Therapeutics in $8.7 billion all-cash deal
By Claudia Assis
Abbvie, Cerevel deal is 'significant growth opportunity' for AbbVie
AbbVie Inc. said late Wednesday it has agreed to buy Cerevel Therapeutics Holdings Inc. for $8.7 billion, saying that Cerevel's "robust" neuroscience pipeline adds medications that may transform standards of care in psychiatric and neurological illnesses.
Under the terms of the deal, AbbVie will acquire all shares of Cerevel for $45.00 a share in cash, which values the Cambridge, Mass., neurosciences company at $8.7 billion.
The boards of both companies have approved the transaction, which is expected to close in mid-2024 subject to Cerevel shareholder approval and other usual closing conditions, AbbVie said.
Cerevel's stock (CERE) jumped 14% in extended trading after the news before trading was halted, while shares of AbbVie (ABBV) dropped 1.3%.
Cerevel has multiple medications in clinical-stage and preclinical stages for diseases including schizophrenia and Parkinson's, as well as for mood disorders.
"Our existing neuroscience portfolio and our combined pipeline with Cerevel represents a significant growth opportunity well into the next decade," AbbVie Chief Executive Richard A. Gonzalez said in a statement.
The companies highlighted a few of Cerevel's medications on late-stage trials, including emraclidine, which they called "a potential best-in-class, next-generation" antipsychotic drug that may be effective in treating schizophrenia and Alzheimer's-related psychosis.
AbbVie said that the deal is expected to add to its adjusted per-share earnings by 2030.
-Claudia Assis
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
12-06-23 1659ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back